Esperion Therapeutics ESPR EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's EPS (diluted)?
- Esperion Therapeutics (ESPR) reported EPS (diluted) of -$0.10 in Q1 2026.
- How has Esperion Therapeutics's EPS (diluted) changed year-over-year?
- Esperion Therapeutics's EPS (diluted) increased by 52.4% year-over-year, from -$0.21 to -$0.10.
- What is the long-term trend for Esperion Therapeutics's EPS (diluted)?
- Over 3 years (2021 to 2024), Esperion Therapeutics's EPS (diluted) has grown at a -70.1% compound annual growth rate (CAGR), from -$9.32 to -$0.25.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.